BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17692976)

  • 1. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
    Fonteyne V; De Neve W; Villeirs G; De Wagter C; De Meerleer G
    Radiother Oncol; 2007 Aug; 84(2):156-63. PubMed ID: 17692976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.
    De Meerleer G; Fonteyne V; Meersschout S; Van den Broecke C; Villeirs G; Lumen N; Ost P; Vandecasteele K; De Neve W
    Radiother Oncol; 2008 Nov; 89(2):205-13. PubMed ID: 18771809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy.
    Fokdal L; Honoré H; Høyer M; von der Maase H
    Radiother Oncol; 2005 Feb; 74(2):203-10. PubMed ID: 15734208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer.
    Skala M; Rosewall T; Dawson L; Divanbeigi L; Lockwood G; Thomas C; Crook J; Chung P; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):690-8. PubMed ID: 17379434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.
    Peeters ST; Lebesque JV; Heemsbergen WD; van Putten WL; Slot A; Dielwart MF; Koper PC
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1151-61. PubMed ID: 16414208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
    Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
    Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Coote JH; Wylie JP; Cowan RA; Logue JP; Swindell R; Livsey JE
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1121-7. PubMed ID: 19131179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
    Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer.
    Koper PC; Heemsbergen WD; Hoogeman MS; Jansen PP; Hart GA; Wijnmaalen AJ; van Os M; Boersma LJ; Lebesque JV; Levendag P
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1072-82. PubMed ID: 15001247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
    Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
    van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.
    Fonteyne V; Villeirs G; Lumen N; De Meerleer G
    Radiother Oncol; 2009 Jul; 92(1):42-7. PubMed ID: 19356817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.